Eine vergleichende Kostenanalyse von sechs Anticholinergika zur Behandlung der überaktiven Blase und Inkontinenz in DeutschlandReportar como inadecuado




Eine vergleichende Kostenanalyse von sechs Anticholinergika zur Behandlung der überaktiven Blase und Inkontinenz in Deutschland - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

PharmacoEconomics German Research Articles

, Volume 11, Issue 2, pp 65–76

First Online: 31 January 2014

Abstract

ObjectiveComparing the costs of solifenacin, oxybutynin, trospium chloride, tolterodine, propiverine, and darifenacin for the treatment of overactive bladder OAB and incontinence in Germany.

Data and methodsCosts are assessed from a public health insurance perspective. The study is based on a unique sickness fund dataset of 2.9 million insured persons which includes records on outpatient care, inpatient care, pharmaceuticals, adjuvant therapies, and medical aids for 2009. 24,039 persons received anticholinergics and were thus classified as OAB patients. 4,152 of these patients also suffered from incontinence. Multiple linear regression models were performed, controlling for age and gender effects on costs.

ResultsOAB patients caused additional costs of € 782 compared to non-OAB patients. Patients treated with propiverine had the lowest additional costs € 691 and patients treated with tolterodine the highest € 1,124. In the special case of incontinence, patients treated with solifenacin incurred by far the lowest additional costs € 1,320, patients treated with tolterodine the highest € 2,198. The low treatment costs for solifenacin are mainly driven by lower spending on medical aids, especially due to lower pad usage. All results are highly significant p<0.01.

ConclusionOAB patients treated with propiverine and incontinent patients treated with solifenacin have the lowest additional costs. In both patient groups tolterodine is associated with the highest additional cost of treatment.

Download fulltext PDF



Autor: Stefan Felder - Thomas Mayrhofer

Fuente: https://link.springer.com/







Documentos relacionados